These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 29110615)

  • 1. Effects of Molecular Hydrogen Assessed by an Animal Model and a Randomized Clinical Study on Mild Cognitive Impairment.
    Nishimaki K; Asada T; Ohsawa I; Nakajima E; Ikejima C; Yokota T; Kamimura N; Ohta S
    Curr Alzheimer Res; 2018 Mar; 15(5):482-492. PubMed ID: 29110615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Validation of the Hungarian version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild cognitive impairment].
    Papp E; Pákáski M; Drótos G; Kálmán J
    Psychiatr Hung; 2012; 27(6):426-34. PubMed ID: 23429337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.
    Henderson ST; Vogel JL; Barr LJ; Garvin F; Jones JJ; Costantini LC
    Nutr Metab (Lond); 2009 Aug; 6():31. PubMed ID: 19664276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Anserine/Carnosine Supplementation on Mild Cognitive Impairment with APOE4.
    Masuoka N; Yoshimine C; Hori M; Tanaka M; Asada T; Abe K; Hisatsune T
    Nutrients; 2019 Jul; 11(7):. PubMed ID: 31319510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
    Sparks DL; Connor DJ; Sabbagh MN; Petersen RB; Lopez J; Browne P
    Acta Neurol Scand Suppl; 2006; 185():3-7. PubMed ID: 16866904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia.
    Kile S; Au W; Parise C; Rose K; Donnel T; Hankins A; Chan M; Ghassemi A
    J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):106-112. PubMed ID: 26420886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Therapeutic Efficacy of Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease.
    Rosenbloom M; Barclay TR; Kashyap B; Hage L; O'Keefe LR; Svitak A; Pyle M; Frey W; Hanson LR
    Drugs Aging; 2021 May; 38(5):407-415. PubMed ID: 33719017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the utility of everyday memory test and the Alzheimer's Disease Assessment Scale-Cognitive part for evaluation of mild cognitive impairment and very mild Alzheimer's disease.
    Adachi H; Shinagawa S; Komori K; Toyota Y; Mori T; Matsumoto T; Sonobe N; Kashibayashi T; Ishikawa T; Fukuhara R; Ikeda M
    Psychiatry Clin Neurosci; 2013 Apr; 67(3):148-53. PubMed ID: 23581865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidative stress and APO E polymorphisms in Alzheimer's disease and in mild cognitive impairment.
    Chico L; Simoncini C; Lo Gerfo A; Rocchi A; Petrozzi L; Carlesi C; Volpi L; Tognoni G; Siciliano G; Bonuccelli U
    Free Radic Res; 2013 Aug; 47(8):569-76. PubMed ID: 23668794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
    Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M
    J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening of mild cognitive impairment in Chinese older adults--a multistage validation of the Chinese abbreviated mild cognitive impairment test.
    Lam LC; Tam CW; Lui VW; Chan WC; Chan SS; Chiu HF; Leung T; Tham MK; Ho KS; Chan WM
    Neuroepidemiology; 2008; 30(1):6-12. PubMed ID: 18204291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, open-label clinical trial in mild cognitive impairment with EGb 761 examining blood markers of inflammation and oxidative stress.
    Morató X; Marquié M; Tartari JP; Lafuente A; Abdelnour C; Alegret M; Jofresa S; Buendía M; Pancho A; Aguilera N; Ibarria M; Diego S; Cuevas R; Cañada L; Calvet A; Antonio EE; Pérez-Cordón A; Sanabria Á; de Rojas I; Nuñez-Llaves R; Cano A; Orellana A; Montrreal L; Cañabate P; Rosende-Roca M; Vargas L; Bojaryn U; Ricciardi M; Ariton DM; Espinosa A; Ortega G; Muñoz N; Lleonart N; Alarcón-Martín E; Moreno M; Preckler S; Tantinya N; Ramis M; Nogales AB; Seguer S; Martín E; Pytel V; Valero S; Gurruchaga M; Tárraga L; Ruiz A; Boada M
    Sci Rep; 2023 Apr; 13(1):5406. PubMed ID: 37012306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population.
    Prins ND; van der Flier WM; Brashear HR; Knol DL; van de Pol LA; Barkhof F; Scheltens P
    J Alzheimers Dis; 2013; 36(1):79-85. PubMed ID: 23563246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of brain structure and cognitive function in the Alzheimer's disease neuroimaging initiative.
    Song X; Mitnitski A; Zhang N; Chen W; Rockwood K;
    J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):71-8. PubMed ID: 23123510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hierarchical Bayesian cognitive processing models to analyze clinical trial data.
    Shankle WR; Hara J; Mangrola T; Hendrix S; Alva G; Lee MD
    Alzheimers Dement; 2013 Jul; 9(4):422-8. PubMed ID: 23123230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Would older adults with mild cognitive impairment adhere to and benefit from a structured lifestyle activity intervention to enhance cognition?: a cluster randomized controlled trial.
    Lam LC; Chan WC; Leung T; Fung AW; Leung EM
    PLoS One; 2015; 10(3):e0118173. PubMed ID: 25826620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Study of Mental and Resistance Training (SMART) study—resistance training and/or cognitive training in mild cognitive impairment: a randomized, double-blind, double-sham controlled trial.
    Fiatarone Singh MA; Gates N; Saigal N; Wilson GC; Meiklejohn J; Brodaty H; Wen W; Singh N; Baune BT; Suo C; Baker MK; Foroughi N; Wang Y; Sachdev PS; Valenzuela M
    J Am Med Dir Assoc; 2014 Dec; 15(12):873-80. PubMed ID: 25444575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of influence of the apolipoprotein E genotype on the outcome of selegiline treatment in Alzheimer's disease.
    Kálmán J; Juhász A; Rimanóczy A; Palotás A; Palotás M; Szabó Z; Boda K; Márki-Zay J; Janka Z
    Dement Geriatr Cogn Disord; 2003; 16(1):31-4. PubMed ID: 12714797
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.